Nuvectis Pharma, Inc. (NVCT) — SEC Filings
Nuvectis Pharma, Inc. (NVCT) — 30 SEC filings. Latest: 10-Q (May 5, 2026). Includes 14 8-K, 7 10-Q, 4 SC 13G/A.
View Nuvectis Pharma, Inc. on SEC EDGAR
Overview
Nuvectis Pharma, Inc. (NVCT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: Nuvectis Pharma, Inc. (NVCT) reported a significant increase in net loss for the three and nine months ended September 30, 2025, primarily driven by increased research and development (R&D) expenses. The net loss for the three months ended September 30, 2025, was $7.46 million, up from $4.15 million
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 25 neutral. The dominant filing sentiment for Nuvectis Pharma, Inc. is neutral.
Filing Type Overview
Nuvectis Pharma, Inc. (NVCT) has filed 7 10-Q, 14 8-K, 2 DEF 14A, 2 10-K, 4 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of NVCT's 23 recent filings, 4 were flagged as high-risk, 5 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$7.46M |
| EPS | -$0.44 |
| Debt-to-Equity | 0.48 |
| Cash Position | $35.44M |
| Operating Margin | N/A |
| Total Assets | $35.59M |
| Total Debt | $11.58M |
Key Executives
- Shay Shemesh
- Ron Bentsur
- Dr. Enrique Poradosu
- Mr. Shay Shemesh
- Mr. Ron Bentsur
Industry Context
Nuvectis Pharma operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and securing substantial funding for progression through development stages.
Top Tags
financials (6) · financial-reporting (4) · 10-Q (4) · corporate-governance (3) · sec-filing (3) · Nuvectis Pharma (3) · beneficial-ownership (3) · Biotechnology (2) · Capital Raise (2) · shareholder-vote (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $7.46M | Increased 80% from $4.15M in Q3 2024 |
| Net Loss (YTD Q3 2025) | $19.13M | Increased 50% from $12.75M in YTD Q3 2024 |
| Research and Development Expenses (Q3 2025) | $5.77M | Increased from $2.82M in Q3 2024 |
| Research and Development Expenses (YTD Q3 2025) | $13.07M | Increased from $8.42M in YTD Q3 2024 |
| Cash and Cash Equivalents (Sept 30, 2025) | $35.44M | Increased from $18.53M at Dec 31, 2024 |
| Net Proceeds from Public Offering (Feb 2025) | $14.0M | Significant capital infusion |
| Net Proceeds from At-the-Market Program (YTD Q3 2025) | $14.9M | Additional capital raised |
| Accumulated Deficit (Sept 30, 2025) | $92.37M | Indicates ongoing losses since inception |
| Common Shares Outstanding (Nov 1, 2025) | 25,614,896 | Reflects recent share issuances and potential dilution |
| Full-time Employees | 13 | Small team requiring growth management |
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating pre-commercial stage |
| Net Loss | $4.5M | for Q2 2025, an increase from $3.8M in Q2 2024 |
| Shares Issued | 150,000 | in Q2 2025 via At-Market Offering, contributing to dilution |
| Par Value | $0.0033 | of common stock issued in offerings |
| Additional Paid-in Capital | $60,000 | Related to Public Offering Member for the period ending March 31, 2025. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Nuvectis Pharma, Inc. (NVCT)?
Nuvectis Pharma, Inc. has 30 recent SEC filings from Jan 2024 to May 2026, including 14 8-K, 7 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NVCT filings?
Across 30 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 25 neutral. The dominant sentiment is neutral.
Where can I find Nuvectis Pharma, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Nuvectis Pharma, Inc. (NVCT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Nuvectis Pharma, Inc.?
Key financial highlights from Nuvectis Pharma, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NVCT?
The investment thesis for NVCT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Nuvectis Pharma, Inc.?
Key executives identified across Nuvectis Pharma, Inc.'s filings include Shay Shemesh, Ron Bentsur, Dr. Enrique Poradosu, Mr. Shay Shemesh, Mr. Ron Bentsur.
What are the main risk factors for Nuvectis Pharma, Inc. stock?
Of NVCT's 23 assessed filings, 4 were flagged high-risk, 5 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Nuvectis Pharma, Inc.?
Forward guidance and predictions for Nuvectis Pharma, Inc. are extracted from SEC filings as they are enriched.